stockportfolio.pro
Liquidia Corporation (LQDA)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqCM
Liquidia Corporation revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $8.07M | $739,628 | $12.85M | $15.94M | $17.49M | $14.00M | $158.32M |
| Gross profit | — | $501,916 | $9.83M | $13.08M | $14.60M | $8.12M | $145.08M |
| Net income | $-47.58M | $-59.76M | $-34.58M | $-41.02M | $-78.50M | $-128.29M | $-68.92M |
| Net margin | -589.5% | -8080.1% | -269.0% | -257.4% | -448.9% | -916.6% | -43.5% |
Source: Liquidia Corporation SEC filings (10-K).
Explore 7 years of Liquidia Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track LQDA in your portfolio →
Liquidia Corporation financial history by metric
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Liquidia Corporation — frequently asked questions
What is Liquidia Corporation's revenue?
Liquidia Corporation (LQDA) reported revenue of $158.32M for fiscal year 2025, up 1031.2% from the prior year, according to its SEC filings.
Is Liquidia Corporation profitable?
No — LQDA reported a net loss of $-68.92M in fiscal 2025.
What is LQDA's P/E ratio?
Liquidia Corporation trades at a price-to-earnings ratio of about 410.7 based on the latest data in our nightly-refreshed cache.
How fast is Liquidia Corporation growing?
LQDA's revenue grew at roughly 192.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Liquidia Corporation have?
As of fiscal year 2025, LQDA carried roughly $191.34M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Liquidia Corporation's gross margin?
LQDA's gross margin was 91.6% in fiscal 2025 — gross profit of $145.08M on revenue of $158.32M.
What is Liquidia Corporation's market cap?
Liquidia Corporation (LQDA) has a market capitalization of about $6.21B, based on the latest data in our nightly-refreshed cache.
When does Liquidia Corporation's fiscal year end?
LQDA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Liquidia Corporation's official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.